The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events. This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.
Study Type
OBSERVATIONAL
Enrollment
2,672
Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
Unnamed facility
Many Locations, Albania
Unnamed facility
Many Locations, Bosnia and Herzegovina
Unnamed facility
Many Locations, Kazakhstan
Unnamed facility
Many Locations, Moldova
Time until improvement of acute exacerbation
Time frame: End of study
Time until cure of acute exacerbation
Time frame: End of study
Severity of AECB according to Antonisen criteria
Time frame: Baseline
Impact of AECB on daily life activities
Time frame: Baseline
Safety of Avelox under daily life treatment conditions
Time frame: Throughout treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Many Locations, North Macedonia
Unnamed facility
Many Locations, Russia
Unnamed facility
Many Locations, Slovakia
Unnamed facility
Many Locations, Ukraine